Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARFISH: Screening Trial for Pain Relief in Schwannomatosis
NCT05684692Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2023
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of siltuximab, erenumab in schwannomatosis, chronic pain, sponsored by Massachusetts General Hospital. Started Aug 2023; status: recruiting.
02
Drugs
siltuximaberenumab
03
Conditions
schwannomatosischronic pain
Beyond the preview
Go deeper on NCT05684692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05684692.